Opthea Limited (OPT) develops and commercialise therapies primarily for eye disease. Opthea’s lead asset, OPT -302, is a soluble form of VEGFR-3 in clinical development as a novel therapy for wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME). The Group operates in one industry and one geographical area, those being the biotechnology and healthcare industry and Australia.
Opthea Limited belongs to Health Care sector and under industry of Biotechnology. You can get more information about this company via their website: http://www.opthea.com.
This a small cap company with market cap of 527 millions.
Compared to Market and Sector
The following table compares the company to Market and Sector based on Earning, Price/Earning ratio(P/E), Price/Book ratio (P/B) and PE growth.
Company PE is less than both sector and market. while Company PB is greater than both sector and market. On the other hand, Company Earning is less than both sector and market.
Dividend Growth Chart
The following chart shows you how opt dividend grows in the recent years.